drugset / Trial / NCT06603974
The Efficacy and Safety of Benmelstobart for GC/EGC
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the major pathological response (MPR) rate of locally advanced gastric cancer / gastroesophageal junction cancer treated with bemosumab combined with antiangiogenic drugs and neoadjuvant chemotherapy. Researchers will use drug Benmelstobart in combination with antiangiogenesis drugs and newadjuvant chemotherapy to see if the drug works to treat locally advanced gastric cancer / gastroesophageal junction cancer. Participants will:injection drug Benmelstobart，On the first day of each cycle, 3 weeks (21 days) were a treatment cycle.
Timeline
- Start
- 2024-10-16
- Primary completion
- 2026-07-26
- Completion
- 2026-12-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Benmelstobart | Monoclonal antibody | 1200 mg | — |
| Background | Oxaliplatin | Small molecule | 130 mg/m2 | — |
| Background | Paclitaxel | Small molecule | 260 mg/m2 | Intravenous |
| Background | S-1 | Small molecule | 40 mg | Oral |
| Background | S-1 | Small molecule | 50 mg | Oral |
| Background | S-1 | Small molecule | 60 mg | Oral |